

Coverage of any drug intervention discussed in a Medica prior authorization guideline is subject to the limitations and exclusions outlined in the member's benefit certificate or policy and applicable state and/or federal laws.

☐ **Commercial (Small & Large Group)** ☐ **ASO** ☐ **Exchange/ACA**
☒ **Medicare Advantage (MAPD)**

Medicare Part B Step Therapy**MB2011****Covered Service:** Yes**Prior Authorization
Required:** Yes**Additional
Information:**

This Medical Benefit Injectable Policy is provided for informational purposes only and does not constitute medical advice. Treating physicians and health care providers are solely responsible for making any decisions about medical care. Each class of medical benefit drugs covered under Medicare Part B referenced below includes preferred drugs(s)/product(s) that do not require prior authorization. Prior authorization for a non-preferred drug/product will generally require history of use of a preferred drug/product within the same medical benefit drug class, among other criteria. If a provider administers a non-preferred drug/product without obtaining prior authorization, The Health plan may deny claims for the non-preferred drug/product. The classes of medical benefit drugs that include nonpreferred drug(s)/product(s) subject to prior authorization, and preferred drug(s)/product(s), are listed in this policy.

This policy supplements Medicare NCDs, LCDs, and manuals for the purpose of determining coverage under Medicare Part B medical benefits. This policy implements a prior authorization requirement for prescriptions or administrations of medical benefit drugs only. A member cannot be required under this policy to change a current drug/product. For the purposes of this policy, a current drug/product means the member has a paid claim for the drug/product within the past 365 days.

A non-preferred drug/product must satisfy the following criteria. If a provider administers a non-preferred drug/ product without obtaining prior authorization, The Health plan may deny claims for the non-preferred drug/product.

Health Plan Approved Criteria:**This Policy applies to step therapy for the following drugs/products:****A. Bisphosphonate (alendronate, ibandronate or risedronate, Prolia, Evenity)****1. Applicable Drugs**

Coverage of any drug intervention discussed in a Medica prior authorization guideline is subject to the limitations and exclusions outlined in the member's benefit certificate or policy and applicable state and/or federal laws.

- i. **Preferred drug(s): alendronate, ibandronate or risedronate**
- ii. **Non-preferred drug(s): Prolia, Evenity (for Dx of osteoporosis with high risk of fractures.)**

Non-Preferred Product Step Therapy Criteria

Prolia/Evenity may be used when all of the criteria listed under ONE of the following sections A., B., or C. are satisfied:

A. All of the following:

1. History of use of Prolia, alendronate, ibandronate or risedronate resulting in minimal clinical response to therapy with high risk fractures; and
2. Physician attests that in their clinical opinion the clinical response would be expected to be superior with Prolia than with alendronate, ibandronate or risedronate
3. Physician attests that in their clinical opinion the clinical response would be expected to be superior with Evenity than with Prolia, alendronate, ibandronate or risedronate

OR

B. All of the following:

1. History of intolerance or adverse event to alendronate, ibandronate or risedronate and
2. Physician attests that in their clinical opinion the same intolerance or adverse event would not be expected to occur with Prolia or Evenity; and
3. For patients, who are unable to tolerate Prolia, alendronate, ibandronate or risedronate or in the rare instance that Prolia, alendronate, ibandronate or risedronate is contraindicated for a patient, documentation is required that clearly indicates the reason that the patient cannot use Prolia, alendronate, ibandronate or risedronate .

OR

C. Continuation of prior therapy within the past 365 day

HCPCS Codes	Description
No codes	alendronate, ibandronate or risedronate
J0897	Prolia
	Evenity

Coverage of any drug intervention discussed in a Medica prior authorization guideline is subject to the limitations and exclusions outlined in the member's benefit certificate or policy and applicable state and/or federal laws.

B. Sick Cell (Hydroxyurea, Adaveko)**1. Applicable Drugs**

- i. Preferred drug(s): Hydroxyurea**
- ii. Non-preferred drug(s): Adakveo**

Non-Preferred Product Step Therapy Criteria

Adaveko may be used when all of the criteria listed under ONE of the following sections A., B., or C. are satisfied:

A. All of the following:

- 1. History of use of Hydroxyurea resulting in minimal clinical response to therapy; and
- 2. Physician attests that in their clinical opinion the clinical response would be expected to be superior with Adakveo than with Hydroxyurea.

OR

B. All of the following:

- 1. History of intolerance or adverse event to Hydroxyurea and
- 2. Physician attests that in their clinical opinion the same intolerance or adverse event would not be expected to occur with Adakveo; and
- 3. For patients, who are unable to tolerate Hydroxyurea or in the rare instance that Hydroxyurea is contraindicated for a patient, documentation is required that clearly indicates the reason that the patient cannot use Hydroxyurea.

OR

C. Continuation of prior therapy within the past 365 day

HCPSC Codes	Description
N/a	Hydroxyurea
J0791	Adakveo

Coverage of any drug intervention discussed in a Medica prior authorization guideline is subject to the limitations and exclusions outlined in the member's benefit certificate or policy and applicable state and/or federal laws.

C. Migraine (Emgality, Aimovig and Vyepti)**1. Applicable Drugs**

- i. Preferred drug(s): Emgality and Aimovig**
- ii. Non-preferred drug(s): Vyepti**

Non-Preferred Product Step Therapy Criteria

Vyepti may be used when all of the criteria listed under ONE of the following sections A., B., or C. are satisfied:

A. All of the following:

- 1. History of use of Emgality or Aimovig resulting in minimal clinical response to therapy; and
- 2. Physician attests that in their clinical opinion the clinical response would be expected to be superior with Vyepti than with Emgality or Aimovig.

OR

B. All of the following:

- 4. History of intolerance or adverse event to Aimovig or Emgality and
- 5. Physician attests that in their clinical opinion the same intolerance or adverse event would not be expected to occur with Vyepti; and
- 6. For patients, who are unable to tolerate Aimovig and Emgality or in the rare instance that Aimovig or Emgality are contraindicated for a patient, documentation is required that clearly indicates the reason that the patient cannot use Aimovig or Emgality .

OR

C. Continuation of prior therapy within the past 365 day

HCPCS Codes	Description
J8499	Aimovig
J8499	Emgality
J3032	Vyepti

Coverage of any drug intervention discussed in a Medica prior authorization guideline is subject to the limitations and exclusions outlined in the member's benefit certificate or policy and applicable state and/or federal laws.

D. Systemic Lupus Disease (Oral or injectable Hydroxychloroquine, methotrexate, azathioprine, mycophenolate)

1. Applicable Drugs

- i. Preferred drug(s): Oral or injectable Hydroxychloroquine, methotrexate, azathioprine, mycophenolate**
- ii. Non-preferred drug(s): Benlysta or Saphnelo**

Non-Preferred Product Step Therapy Criteria

Benlysta or Saphnelo may be used when all of the criteria listed under ONE of the following sections A., B., or C. are satisfied:

A. All of the following:

- 1. History of use with (1) of the following (IV or Oral) :
 - i. Oral: Hydroxychloroquine, methotrexate, azathioprine, mycophenolate OR
 - ii. Intravenous: Hydroxychloroquine, methotrexate, azathioprine, mycophenolate
- 2. Physician attests that in their clinical opinion the clinical response would be expected to be superior with Benlysta or Saphnelo than with preferred products.

OR

B. All of the following:

- 1. History of intolerance or adverse event to Preferred product and
- 2. Physician attests that in their clinical opinion the same intolerance or adverse event would not be expected to occur with benlysta and / or saphnelo; and
- 3. For patients, who are unable to tolerate Preferred products or in the rare instance that preferred products are contraindicated for a patient, documentation is required that clearly indicates the reason that the patient cannot use any of the preferred products .

OR

C. Continuation of prior therapy within the past 365 day

HCPCS Codes	Description
N/A	Hydroxychloroquine
N/A	Methotrexate

Coverage of any drug intervention discussed in a Medica prior authorization guideline is subject to the limitations and exclusions outlined in the member's benefit certificate or policy and applicable state and/or federal laws.

N/A	Azathiopurine
N/A	Mycophenolate
J0490	Benlysta
J3590	Saphnelo

E. Gout treatment (Allopurinol, Febuxostat, Krystexxa)

1. Applicable Drugs

- i. Preferred drug(s): Allopurinol, Febuxostat**
- ii. Non-preferred drug(s): Krystexxa**

Non-Preferred Product Step Therapy Criteria

Krystexxa may be used when all of the criteria listed under (1) ONE of the following sections A., B., or C. are satisfied:

A. All of the following:

- 1. History of use with Allopurinol or Febuxostat
- 2. Physician attests that in their clinical opinion the clinical response would be expected to be superior with Krystexxa than with preferred products.

OR

B. All of the following:

- 1. History of intolerance or adverse event to Preferred product and
- 2. Physician attests that in their clinical opinion the same intolerance or adverse event would not be expected to occur with Krystexxa; and
- 3. For patients, who are unable to tolerate Preferred products or in the rare instance that preferred products are contraindicated for a patient, documentation is required that clearly indicates the reason that the patient cannot use any of the preferred products .

OR

C. Continuation of prior therapy within the past 365 day

HCPCS Codes	Description
n/a	Allopurinol
n/a	Febuxostat
J2507	Krystexxa

Coverage of any drug intervention discussed in a Medica prior authorization guideline is subject to the limitations and exclusions outlined in the member's benefit certificate or policy and applicable state and/or federal laws.

F. Crohns Disease (Tysabri, Entyvio)

1. Applicable Drugs

- i. **Preferred drug(s):**; Formulary self-injectable TNF- α inhibitors (e.g. HUMIRA); Formulary medical benefit infusables an infliximab product
- i. **Non-preferred drug(s): Tysabri, Entyvio**

Non-Preferred Product Step Therapy Criteria

Tysabri or Entyvio may be used when all of the criteria listed under ONE of the following sections A., B., or C. are satisfied:

A. For Tysabri and Entyvio the following:

- 1. History of use with 1 of the following Prior to Tysabri and Entyvio : self-injectable TNF- α inhibitors (e.g. HUMIRA); Formulary medical benefit infusables, infliximab.
- 1. Physician attests that in their clinical opinion the clinical response would be expected to be superior with Tysabri or Entyvio than with preferred products because member has an aggressive disease

OR

B. All of the following:

- 1. History of intolerance or adverse event to Preferred product and
- 2. Physician attests that in their clinical opinion the same intolerance or adverse event would not be expected to occur with Ocrevus and
- 3. For patients, who are unable to tolerate Preferred products or in the rare instance that preferred products are contraindicated for a patient, documentation is required that clearly indicates the reason that the patient cannot use any of the preferred products .

OR

C. Continuation of prior therapy within the past 365 day

Description	HCPSC Codes
Tysabri	J2323
Entyvio	J3380

Coverage of any drug intervention discussed in a Medica prior authorization guideline is subject to the limitations and exclusions outlined in the member's benefit certificate or policy and applicable state and/or federal laws.

G. Rheumatoid Arthritis:**1. Applicable Drugs**

- i. Preferred drugs(Enbrel (etanercept), Humira (adalimumab), infliximab and Rinvoq**
- ii. Non-preferred drug(s) IV or Subcutaneous: Orenzia, Actemra or Simponi Aria**

Non-Preferred Product Step Therapy Criteria

Orenzia, Actemra or Simponi may be used when all of the criteria listed under ONE of the following sections A., B., or C. are satisfied:

A. All of the following:

1. History of use with (2) of the following therapies :
 - i. Enbrel, Humira, Rinvoq or infliximab
2. Physician attests that in their clinical opinion the clinical response would be expected to be superior with Orenzia, Actemra or Simponi than with preferred products.

OR

B. All of the following:

1. History of intolerance or adverse event to Preferred product and
2. Physician attests that in their clinical opinion the same intolerance or adverse event would not be expected to occur with Orenzia, Actemra or Simponi; and
3. For patients, who are unable to tolerate Preferred products or in the rare instance that preferred products are contraindicated for a patient, documentation is required that clearly indicates the reason that the patient cannot use any of the preferred products .

OR

C. Continuation of prior therapy within the past 365 day

HCPCS Codes	Description
N/A	Rinvoq
J0135	Humira
J1438	Enbrel
J0490	infliximab
J0129	Orenzia
J3358	Stelara

Coverage of any drug intervention discussed in a Medica prior authorization guideline is subject to the limitations and exclusions outlined in the member's benefit certificate or policy and applicable state and/or federal laws.

J3262	Actemra
-------	---------

H. Polyarticular juvenile idiopathic arthritis (PJIA):

1. Applicable Drugs

i. Preferred drugs(Enbrel (etanercept), Humira (adalimumab),Inj Methotrexate

ii. Non-preferred drug(s) IV or Subcutaneous: Orencia, Actemra

Non-Preferred Product Step Therapy Criteria

Orencia, Actemra may be used when all of the criteria listed under ONE of the following sections A., B., or C. are satisfied:

A. All of the following:

1. History of use with (2) of the following therapies :
 - i. Enbrel, Humira,injectable Methotrexate
2. Physician attests that in their clinical opinion the clinical response would be expected to be superior with Orencia, Actemra than with preferred products.

OR

B. All of the following:

1. History of intolerance or adverse event to Preferred product and
2. Physician attests that in their clinical opinion the same intolerance or adverse event would not be expected to occur with Orencia, Actemra; and
3. For patients, who are unable to tolerate Preferred products or in the rare instance that preferred products are contraindicated for a patient, documentation is required that clearly indicates the reason that the patient cannot use any of the preferred products .

OR

C. Continuation of prior therapy within the past 365 day

HCP Codes	Description
N/A	Injectable Methotrexate
J0135	Humira
J1438	Enbrel
J0129	Orencia
J3262	Actemra

Coverage of any drug intervention discussed in a Medica prior authorization guideline is subject to the limitations and exclusions outlined in the member's benefit certificate or policy and applicable state and/or federal laws.

I. Psoriatic arthritis:**1. Applicable Drugs**

i. Preferred drugs(Enbrel (etanercept), Humira (adalimumab), Otezla, Cosentyx, Taltz, Stelara

ii. Non-preferred drug(s) IV or Subcutaneous: Orencia, Simponi Aria

Non-Preferred Product Step Therapy Criteria

Orencia, Simponi may be used when all of the criteria listed under ONE of the following sections A., B., or C. are satisfied:

A. All of the following:

1. History of use with (2) of the following therapies :
 - i. Enbrel, Humira, Cosentyx, Taltz, Stelara
2. Physician attests that in their clinical opinion the clinical response would be expected to be superior with Orencia, Simponi than with preferred products.

OR

B. All of the following:

1. History of intolerance or adverse event to Preferred product and
2. Physician attests that in their clinical opinion the same intolerance or adverse event would not be expected to occur with Orencia, Simponi and
3. For patients, who are unable to tolerate Preferred products or in the rare instance that preferred products are contraindicated for a patient, documentation is required that clearly indicates the reason that the patient cannot use any of the preferred products .

OR

C. Continuation of prior therapy within the past 365 day

HCPCS Codes	Description
J1602	Simponi Aria
J0135	Humira
J1438	Enbrel
J0129	Orencia
N/a	Cosentyx
N/a	Taltz

Coverage of any drug intervention discussed in a Medica prior authorization guideline is subject to the limitations and exclusions outlined in the member's benefit certificate or policy and applicable state and/or federal laws.

J3358	Stelara
-------	---------

J. Ankylosing spondylitis:
1. Applicable Drugs

**i. Preferred drugs(Enbrel (etanercept), Humira (adalimumab)
Cosentyx**

ii. Non-preferred drug(s) IV or Subcutaneous: Simponi Aria

Non-Preferred Product Step Therapy Criteria

Simponi may be used when all of the criteria listed under ONE of the following sections A., B., or C. are satisfied:

A. All of the following:

1. History of use with (2) of the following therapies :
 - i. Enbrel, Humira, Cosentyx,
2. Physician attests that in their clinical opinion the clinical response would be expected to be superior with Simponi, than with preferred products.

OR

B. All of the following:

1. History of intolerance or adverse event to Preferred product and
2. Physician attests that in their clinical opinion the same intolerance or adverse event would not be expected to occur with Simponi and
3. For patients, who are unable to tolerate Preferred products or in the rare instance that preferred products are contraindicated for a patient, documentation is required that clearly indicates the reason that the patient cannot use any of the preferred products .

OR

C. Continuation of prior therapy within the past 365 day

HCPCS Codes	Description
J1602	Simponi Aria
J0135	adalimumab
J1438	Entercept
n/a	Cosentyx

K. Asthma

Coverage of any drug intervention discussed in a Medica prior authorization guideline is subject to the limitations and exclusions outlined in the member's benefit certificate or policy and applicable state and/or federal laws.

1. Applicable Drugs

- i. Preferred drug(s): Oral : Systemic Oral corticosteroid, medium or High dose inhaled corticosteroid (ICS) in combination with long-acting beta agonist (LABA), leukotriene receptor antagonist, tiotropium; systemic Injectable: corticosteroids**
- ii. Non-preferred drug(s): Xolair, Cinqair**

Non-Preferred Product Step Therapy Criteria

Xolair or Cinqair may be used when all of the criteria listed under ONE of the following sections A., B., or C. are satisfied:

A. All of the following:

- 1. History of use with (1) of the following (IV or Oral) therapies :
 - i. Systemic Oral corticosteroid, medium or High dose inhaled corticosteroid (ICS) in combination with long-acting beta agonist (LABA), leukotriene receptor antagonist, tiotropium; systemic Injectable: corticosteroids
- 2. Physician attests that in their clinical opinion the clinical response would be expected to be superior with Xolair, Cinqair, than with preferred products.

OR

B. All of the following:

- 1. History of intolerance or adverse event to Preferred product and
- 2. Physician attests that in their clinical opinion the same intolerance or adverse event would not be expected to occur with Xolair, Cinqair; and
- 3. For patients, who are unable to tolerate Preferred products or in the rare instance that preferred products are contraindicated for a patient, documentation is required that clearly indicates the reason that the patient cannot use any of the preferred products .

OR

C. Continuation of prior therapy within the past 365 day

HCPCS Codes	Description
N/A	Oral steroids/IV steroids
N/A	Medium or high dose inhaled corticosteroid
N/A	Long acting beta agonis
N/A	Leukotriene receptor

Coverage of any drug intervention discussed in a Medica prior authorization guideline is subject to the limitations and exclusions outlined in the member's benefit certificate or policy and applicable state and/or federal laws.

J2357	Xolair
J2786	Cinqair

L. Chronic idiopathic Urticaria

1. Applicable Drugs

i. Preferred drug(s): Injectable or oral H1 antihistamines

ii. Non-preferred drug(s): Xolair,

Non-Preferred Product Step Therapy Criteria

Xolair may be used when all of the criteria listed under ONE of the following sections A., B., or C. are satisfied:

A. All of the following:

- History of use with (1) of the following (IV or Oral) therapies :
 - Oral or injectable antihistamines
- Physician attests that in their clinical opinion the clinical response would be expected to be superior with Xolair than with preferred products.

OR

B. All of the following:

- History of intolerance or adverse event to Preferred product and
- Physician attests that in their clinical opinion the same intolerance or adverse event would not be expected to occur with Xolair, and
- For patients, who are unable to tolerate Preferred products or in the rare instance that preferred products are contraindicated for a patient, documentation is required that clearly indicates the reason that the patient cannot use any of the preferred products .

OR

C. Continuation of prior therapy within the past 365 day

HCP Codes	Description
N/A	Oral / IV antihistamines
J2357	Xolair

M. Treatment-resistant Depression

1. Applicable Drugs

Coverage of any drug intervention discussed in a Medica prior authorization guideline is subject to the limitations and exclusions outlined in the member's benefit certificate or policy and applicable state and/or federal laws.

i. Preferred drug: Oral Antidepressants

ii. Non-preferred drug(s): Spravato

Non-Preferred Product Step Therapy Criteria

Spravato may be used when all of the criteria listed under ONE of the following sections A., B., or C. are satisfied:

A. All of the following:

1. History of use with (1) of the following therapies :
 - i. Oral antidepressants
2. Physician attests that in their clinical opinion the clinical response would be expected to be superior with Spravato than with preferred products.

OR

B. All of the following:

1. History of intolerance or adverse event to Preferred product and
2. Physician attests that in their clinical opinion the same intolerance or adverse event would not be expected to occur with Spravato; and
3. For patients, who are unable to tolerate Preferred products or in the rare instance that preferred products are contraindicated for a patient, documentation is required that clearly indicates the reason that the patient cannot use any of the preferred products .

OR

C. Continuation of prior therapy within the past 365 day

HCP Codes	Description
N/A	Oral Antidepressants
S0013	Spravato

N. Iron Replacement

1. Applicable Drugs

i. Preferred drug: Venofer/Infed/Ferrecit/Fereheme

ii. Non-preferred drug(s): Triferic/Injectafer/Monoferric/Triferic AVNU

Non-Preferred Product Step Therapy Criteria

Coverage of any drug intervention discussed in a Medica prior authorization guideline is subject to the limitations and exclusions outlined in the member's benefit certificate or policy and applicable state and/or federal laws.

Triferic/Injectafer/Monoferic/Triferic AVNU may be used when all of the criteria listed under ONE of the following sections A., B., or C. are satisfied:

D. All of the following:

1. History of use with (1) of the following therapies :
 - i. Venofer/Infed/Ferrecit/fereheme
2. Physician attests that in their clinical opinion the clinical response would be expected to be superior with Triferic/Injectafer/Monoferic/Triferic AVNU than with preferred products.

OR

E. All of the following:

4. History of intolerance or adverse event to Preferred product and
5. Physician attests that in their clinical opinion the same intolerance or adverse event would not be expected to occur with Triferic/Injectafer/Monoferic/Triferic AVNU ; and
6. For patients, who are unable to tolerate Preferred products or in the rare instance that preferred products are contraindicated for a patient, documentation is required that clearly indicates the reason that the patient cannot use any of the preferred products .

OR

F. Continuation of prior therapy within the past 365 day

HCP Codes	Description
J1758	Venofer
J2750	Infed
J2917	Ferrecit
Q0138	Fereheme
J1446/J1444	Triferic
J1439	Injectafer
J1437	Monoferic
J1445	Triferic AVNU

O. Skeletal related events with Multiple Myeloma and Prevention of hypercalcemia of malignancy

1. Applicable Drugs

Coverage of any drug intervention discussed in a Medica prior authorization guideline is subject to the limitations and exclusions outlined in the member's benefit certificate or policy and applicable state and/or federal laws.

- i. **Preferred drug(s): Reclast (Zolendronic acid)**
- ii. **Non-preferred drug(s): Xgeva**

Non-Preferred Product Step Therapy Criteria

Xgeva may be used when all of the criteria listed under ONE of the following sections A., B., or C. are satisfied:

D. All of the following:

- 1. History of use of Reclast resulting in minimal clinical response to therapy with high risk fractures; and
- 2. Physician attests that in their clinical opinion the clinical response would be expected to be superior with Xgeva than with Reclast
- 3.

OR

E. All of the following:

- 4. History of intolerance or adverse event to Reclast and
- 5. Physician attests that in their clinical opinion the same intolerance or adverse event would not be expected to occur with Xgeva; and
- 6. For patients, who are unable to tolerate Reclast or in the rare instance that Reclast, is contraindicated for a patient, documentation is required that clearly indicates the reason that the patient cannot use Reclast .

OR

F. Continuation of prior therapy within the past 365 day

HCPCS Codes	Description
J3489	Reclast
J0897	Xgeva

P. Erythropoietic Agents (Procrit, Retacrit)

1. Applicable Drugs

- i. **Preferred drug(s): Retacrit**
- ii. **Non-preferred drug(s): Procrit**

Non-Preferred Product Step Therapy Criteria

Procrit may be used when all of the criteria listed under ONE of the following sections A., B., or C. are satisfied:

Coverage of any drug intervention discussed in a Medica prior authorization guideline is subject to the limitations and exclusions outlined in the member's benefit certificate or policy and applicable state and/or federal laws.

A. All of the following:

1. History of use of Retacrit resulting in minimal clinical response to therapy; and
2. Physician attests that in their clinical opinion the clinical response would be expected to be superior with Procrit than with Retacrit.

OR

B. All of the following:

1. History of intolerance or adverse event to Retacrit;
2. Physician attests that in their clinical opinion the same intolerance or adverse event would not be expected to occur with Procrit; and
3. For patients, who are unable to tolerate Retacrit or in the rare instance that Retacrit is contraindicated for a patient, documentation is required that clearly indicates the reason that the patient cannot use Retacrit.

OR

C. Continuation of prior therapy within the past 365 days.

HCPCS Codes	Description
J0885	Injection, epoetin alfa, (Procrit) (for non-ESRD use), 1000 units
Q5106*	Injection, epoetin alfa, biosimilar, (Retacrit) (for non-ESRD use), 1000 unit

Q. Infliximab (Inflectra, Remicade, Renflexis, Avsola)

1. Applicable Drugs

- i. Preferred drug(s): Renflexis
- ii. Non-preferred drug(s): Remicade, Avsola, Inflectra

Non-Preferred Product Step Therapy Criteria

Remicade, Inflectra or Avsola may be used when all of the criteria listed under ONE of the following sections A., B., or C. are satisfied:

A. All of the following:

1. Trial of at least 14 weeks of Renflexis resulting in minimal clinical response to therapy and residual disease activity; and
2. Physician attests that in their clinical opinion the clinical response would be expected to be superior with Remicade, Avsola or Inflectra than with Renflexis.

Coverage of any drug intervention discussed in a Medica prior authorization guideline is subject to the limitations and exclusions outlined in the member's benefit certificate or policy and applicable state and/or federal laws.

OR

B. All of the following:

1. History of intolerance or adverse event to Renflexis;
2. Physician attests that in their clinical opinion the same intolerance or adverse event would not be expected to occur with Remicade, Avsola and Inflectra, and
3. For patients, who are unable to tolerate Renflexis or in the rare instance that Renflexis is contraindicated for a patient, documentation is required that clearly indicates the reason that the patient cannot use Renflexis.

OR

C. Continuation of prior therapy within the past 365 days.

HCPSC Codes	Description
J1745	Injection, infliximab, (Remicade), 10 mg
Q5103*	Injection, infliximab-dyyb, biosimilar, (Inflectra), 10 mg
Q5104*	Injection, infliximab-abda, biosimilar, (Renflexis), 10 mg
Q5121	Injection, infliximab-axxq, biosimilar, (Avsola), 10mg

R. Colony Stimulating Factors Short-Acting (Granix, Neupogen, Nivestym, Zarxio)

1. Applicable Drugs

- i. Preferred drug(s): Zarxio, Nivestym
- ii. Non-preferred drug(s): Granix, Neupogen, Leukine

Non-Preferred Product Step Therapy Criteria

Granix, Leukine or Neupogen may be used when all of the criteria listed under ONE of the following sections A., B., or C. are satisfied:

A. Both of the following:

1. History of use of Zarxio or Nivestym resulting in minimal clinical response to therapy; and
2. Physician attests that in their clinical opinion the clinical response would be expected to be superior with Neupogen, Leukine or Granix than with Zarxio and Nivestym.

OR

B. All of the following:

- 1 History of intolerance or adverse event to Zarxio or Nivestym;

Coverage of any drug intervention discussed in a Medica prior authorization guideline is subject to the limitations and exclusions outlined in the member's benefit certificate or policy and applicable state and/or federal laws.

- 2 Physician attests that in their clinical opinion the same intolerance or adverse event would not be expected to occur with Neupogen, Leukine or Granix; and
- 3 For patients, who are unable to tolerate Zarxio or Nivestym in the rare instance that Zarxio or Nivestym is contraindicated for a patient, documentation is required that clearly indicates the reason that the patient cannot use Zarxio or Nivestym.

OR

C. Continuation of prior therapy within the past 365 days.

HCPSC Codes	Description
J1442	Injection, filgrastim (G-CSF), (Neupogen) excludes biosimilars, 1 mcg J1447 Injection, tbo-filgrastim, (Granix)1 microgram
Q5101*	Injection, filgrastim-sndz, biosimilar, (Zarxio) 1 microgram
Q5110	Injection, filgrastim-aafi, biosimilar,(Nivestym), 1 microgram
J2820	Injection, sargramostim (GM-CSF), (Leukine), 50mcg

S. Colony Stimulating Factors Long-Acting (Neulasta, Udenyca, Fulphila, Ziextenzo)

a. Applicable Drugs

- i. Preferred drug(s): , Fulphila, Ziextenzo, Nyprevia
- ii. Non-preferred drug(s): Neulasta, Udenyca

Non-Preferred Product Step Therapy Criteria

Neulasta may be used when all of the criteria listed under ONE of the following sections A., B., or C. are satisfied:

A. All of the following:

1. History of use of Fulphila or Ziextenzo resulting in minimal clinical response to therapy; and
2. Physician attests that in their clinical opinion the clinical response would be expected to be superior with Neulasta and Udenyca than with, Fulphila or Ziextenzo

OR

3. For patients, who are unable to tolerate Fulphila or Ziextenzo or in the rare instance that, Fulphila or Ziextenzo are contraindicated for a patient,

Coverage of any drug intervention discussed in a Medica prior authorization guideline is subject to the limitations and exclusions outlined in the member's benefit certificate or policy and applicable state and/or federal laws.

documentation is required that clearly indicates the reason that the patient cannot use Fulphila or Ziextenzo .

OR

B. Continuation of prior therapy within the past 365 days.

HCPSC Codes	Description
Q5120	Injection, pegfilgrastim-bmez, biosimilar, (Ziextenzo) 0.5mg
J2505	Injection, pegfilgrastim,(Neulasta) 6 mg
Q5108*	Injection, pegfilgrastim-jmdb, biosimilar, (Fulphila), 0.5 mg
Q5111*	Injection, pegfilgrastim-cbqv, biosimilar, (Udenyca), 0.5 mg

*Preferred Drug(s)/Product(s)

T. EGFR inhibitors (Avastin, Mvasi, Zirabev)

1. Applicable Drugs

- i. Preferred drug(s): Mvasi, Zirabev**
- ii. Non-preferred drug(s): Avastin**

Non-Preferred Product Step Therapy Criteria

Avastin may be used when all of the criteria listed under ONE of the following sections A., B., or C. are satisfied:

A. All of the following:

1. History of use of Mvasi or Zirabev resulting in minimal clinical response to therapy; and
2. Physician attests that in their clinical opinion the clinical response would be expected to be superior with than with Avastin.

OR

B. All of the following:

1. History of intolerance or adverse event to Mvasi or Zirabev; and
2. Physician attests that in their clinical opinion the same intolerance or adverse event would not be expected to occur with Avastin; and
3. For patients, who are unable to tolerate Mvasi or Zirabev or in the rare instance that Mvasi or Zirabev is contraindicated for a patient, documentation is required that clearly indicates the reason that the patient cannot use Mvasi or Zirabev.

OR

C. Continuation of prior therapy within the past 365 days

Coverage of any drug intervention discussed in a Medica prior authorization guideline is subject to the limitations and exclusions outlined in the member's benefit certificate or policy and applicable state and/or federal laws.

HCPCS codes	Description
J9035	Injection, bevacizumab, 0.25 mg
Q5107	Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg
Q5189	Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg

U. CD-20 Directed antibody (Rituxan, Truxima, and Ruxience)

1. Applicable Drugs

- i. Preferred drug(s): Truxima and Ruxience**
- ii. Non-preferred drug(s): Rituxan / Rituxan Hycela**

Non-Preferred Product Step Therapy Criteria

Rituxan may be used when all of the criteria listed under ONE of the following sections A., B., or C. are satisfied:

A. All of the following:

1. History of use of Truxima and Ruxience resulting in minimal clinical response to therapy; and
2. Physician attests that in their clinical opinion the clinical response would be expected to be superior with Rituxan than with Truxima and Ruxience

OR

B. All of the following:

1. History of intolerance or adverse event to Truxima and Ruxience and
2. Physician attests that in their clinical opinion the same intolerance or adverse event would not be expected to occur with Rituxan/Rituxan Hycela ; and
3. For patients, who are unable to tolerate Truxima and Ruxience or in the rare instance that Truxima and Ruxience is contraindicated for a patient, documentation is required that clearly indicates the reason that the patient cannot use Truxima and Ruxience.

OR

C. Continuation of prior therapy within the past 365 days

HCPCS Codes	Description
Q5115	Injection, rituximab-abbs, biosimilar, (truxima), 10 mg
Q5119	Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg

Coverage of any drug intervention discussed in a Medica prior authorization guideline is subject to the limitations and exclusions outlined in the member's benefit certificate or policy and applicable state and/or federal laws.

	Rituxan
	Rituxan Hyclea

V. HER 2 Expression (Herzuma, Trazimerz, Kanjinti, Ogivri, Herceptin)

1. Applicable Drugs

- i. Preferred drug(s): Herzuma, Trazimerz**
- ii. Non-preferred drug(s): Herceptin, Kanjinti, Ogivri**

Non-Preferred Product Step Therapy Criteria

Herceptin may be used when all of the criteria listed under ONE of the following sections A., B., or C. are satisfied:

A. All of the following:

1. History of use of Herzuma, Trazimerz, resulting in minimal clinical response to therapy; and
2. Physician attests that in their clinical opinion the clinical response would be expected to be superior with Herceptin, Kanjinti, or Ogivri than with Herzuma, or Trazimerz

OR

B. All of the following:

1. History of intolerance or adverse event to Herzuma, Trazimerz,
2. Physician attests that in their clinical opinion the same intolerance or adverse event would not be expected to occur with Herceptin, Kanjinti or Ogivri; and
3. For patients, who are unable to tolerate or in the rare instance that Herzuma, Trazimerz, is contraindicated for a patient, documentation is required that clearly indicates the reason that the patient cannot use Herzuma, Trazimerz, OR

C. Continuation of prior therapy within the past 365 days

HCPCS Codes	Description
Q5113	Injection, Trastuzumab-pkrb, Biosimilar, (herzuma), 10 Mg
Q5116	Injection, Trastuzumab-qyyp, Biosimilar, (trazimera), 10 Mg
Q5117	Injection, Trastuzumab-anns, Biosimilar, (kanjinti), 10 Mg
Q5114	Injection, Trastuzumab-dkst, Biosimilar, (ogivri), 10 Mg

Coverage of any drug intervention discussed in a Medica prior authorization guideline is subject to the limitations and exclusions outlined in the member's benefit certificate or policy and applicable state and/or federal laws.

J9355	Injection, trastuzumab, excludes biosimilar, 10 mg
-------	--

W. Cholesterol (Injectable Repatha or Praulent)**1. Applicable Drugs**

ii. Preferred drug(s): Repatha Or Praulent

iii. Non-preferred drug(s): Eveeka

Non-Preferred Product Step Therapy Criteria

Eveeka may be used when all of the criteria listed under ONE of the following sections A., B., or C. are satisfied:

A. All of the following:

1. History of use with 1 of the following : Repatha or Praulent
2. Physician attests that in their clinical opinion the clinical response would be expected to be superior with Eveeka than with preferred products.

OR

B. All of the following:

1. History of intolerance or adverse event to Preferred product and
2. Physician attests that in their clinical opinion the same intolerance or adverse event would not be expected to occur with Eveeka and
3. For patients, who are unable to tolerate Preferred products or in the rare instance that preferred products are contraindicated for a patient, documentation is required that clearly indicates the reason that the patient cannot use any of the preferred products .

OR

C. Continuation of prior therapy within the past 365 day

D.

X. Hypercholestermia (Lipitor, Crestor, Leqvio)**1. Applicable Drugs**

iii. Preferred drug(s): Lipitor or Crestor

iv. Non-preferred drug(s): Leqvio

Non-Preferred Product Step Therapy Criteria

Leqvio may be used when all of the criteria listed under ONE of the following sections A., B., or C. are satisfied:

Coverage of any drug intervention discussed in a Medica prior authorization guideline is subject to the limitations and exclusions outlined in the member's benefit certificate or policy and applicable state and/or federal laws.

A. All of the following:

1. History to Unable to meet LDL goal + heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (ASCVD with lipitor or Crestor resulting in minimal clinical response to therapy; and

2 Physician attests that in their clinical opinion the clinical response would be expected to be superior with Leqvio

OR

B. All of the following:

1. History of intolerance or adverse event to Lipitor or Crestor,

2. Physician attests that in their clinical opinion the same intolerance or adverse event would not be expected to occur with Leqvio; and

3. For patients, who are unable to tolerate or in the rare instance that Lipitor or crestor or antilipidic med, is contraindicated for a patient, documentation is required that clearly indicates the reason that the patient cannot use medications, OR

C. Continuation of prior therapy within the past 365 days

HCPCS Codes	Description
	Lipitor
	Crestor
	Leqvio

Comment(s):

1.0 Codes and descriptors listed in this document are provided for informational purposes only and may not be all inclusive or current. Listing of a code in this drug policy does not imply that the service described by the code is a covered or non-covered service. Benefit coverage for any service is determined by the member's policy of health coverage with the plan. Inclusion of a code in the table does not imply any right to reimbursement or guarantee claim payment. Other drug or medical policies may also apply.

2.0 **NOTE: The use of physician samples or manufacturer discounts does not guarantee later coverage under the provisions of the medical certificate and/or pharmacy benefit. All criteria must be met in order to obtain coverage of the listed drug product.**

Coverage of any drug intervention discussed in a Medica prior authorization guideline is subject to the limitations and exclusions outlined in the member's benefit certificate or policy and applicable state and/or federal laws.

	Committee/Source	Date(s)
Document Created:	Medical Policy Committee/Health Services Division/Pharmacy Services	October 21, 2020
Revised:	Medical Policy Committee/Health Services Division/Pharmacy Services	October 20, 2021
	Medical Policy Committee/Health Services Division/Pharmacy Services	April 20, 2022
	Medical Policy Committee/Health Services Division/Pharmacy Services	October 19, 2022
	Medical Policy Committee/Health Services Division/Pharmacy Services	March 15, 2023
	Medical Policy Committee/Health Services Division/Pharmacy Services	December 2023
Reviewed:	Medical Policy Committee/Health Services Division/Pharmacy Services	October 20, 2021
	Medical Policy Committee/Health Services Division/Pharmacy Services	April 20, 2022
	Medical Policy Committee/Health Services Division/Pharmacy Services	October 19, 2022
	Medical Policy Committee/Health Services Division/Pharmacy Services	March 15, 2023
	Medical Policy Committee/Health Services Division/Pharmacy Services	December 2023

Published: 04/01/2024

Effective: 04/01/2024

References:

1. "Highlights of Prescribing information" (Retacrit) see:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125545s000lbl.pdf
Medicare Part B
2. "Highlights of Prescribing Information" (Renflexis) see:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761054orig1s000lbl.pdf 3. For
3. "Highlights of Prescribing Information" (Inflectra) see
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125544s000lbl.pdf 4. For

Coverage of any drug intervention discussed in a Medica prior authorization guideline is subject to the limitations and exclusions outlined in the member's benefit certificate or policy and applicable state and/or federal laws.

4. "Highlights of Prescribing information" (Avsola) see https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761086s000lbl.pdf 5. For
5. "Highlights of Prescribing Information" (Udenyca) see: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761039s000lbl.pdf 6. For
6. "Highlights of Prescribing Information" (Zarxio) see: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125553lbl.pdf 7. For "Highlights of
7. Prescribing Information" (Fulphila) see: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761075s000lbl.pdf 8. For
8. "Highlights of Prescribing Information" (Nivestym) see: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761080s000lbl.pdf 9. For
9. "Highlights of Prescribing Information" (Ziextenzo) see: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761045lbl.pdf
10. Medicare does not have a National Coverage Determination (NCD) for intra-articular injections of sodium hyaluronate. Local Coverage Determinations (LCDs) exist. See: [medadv-coverage-sum/medications-drugoutpatient-partb.pdf](#)
11. <https://www.cms.gov/newsroom/fact-sheets/medicare-advantage-and-part-d-drug-pricing-final-rule-cms-4180-f> 12.
12. <https://www.federalregister.gov/documents/2019/05/23/2019-10521/modernizing-part-d-and-medicare-advantage-to-lower-drug-prices-and-reduce-out-of-pocket-expenses>
13. For CMS Memorandum titled "Prior Authorization and Step Therapy for Part B Drugs in Medicare Advantage", dated August 7, 2018 see: https://www.cms.gov/Medicare/HealthPlans/HealthPlansGenInfo/Downloads/MA_Step_Therapy_HPMS_Memo_8_7_2018.pdf
14. Highlights of Prescribing Information" https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761043lbl.pdf
15. <https://www.uptodate.com/contents/overview-of-the-management-and-prognosis-of-systemic-lupus-erythematosus-in-adults/abstract/88>
16. https://www.regeneron.com/downloads/evkeeza_pi.pdf
17. Highlights for Keystexxa: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/125293s0000lbl.pdf
18. Pillinger MH, Mandell BF. Therapeutic approaches in the treatment of gout. *Semin Arthritis Rheum* 2020; 50:S24.
19. Liana Fraenkel 1, Joan M Bathon 2, Bryant R England 3, E William St Clair 4, Thurayya Arayssi 5, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. *Arthritis Rheumatol* 2021;73:924-39.



(formerly WellFirst Health)

Coverage of any drug intervention discussed in a Medica prior authorization guideline is subject to the limitations and exclusions outlined in the member's benefit certificate or policy and applicable state and/or federal laws.

Wiendl, Heinz et al. "Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)." Therapeutic advances in neurological disorders vol. 14 17562864211039648. 18 Aug. 2021, doi:10.1177/17562864211039648.